Klaric, Kristina-Ana Parai, Jacqueline Louise Kepron, Charis Anthea Walker, Alfredo Eugene Milroy, Christopher Mark
Published in
Journal of clinical pathology
Non-alcoholic steatohepatitis (NASH), fatty liver disease and fibrosis are associated with diabetes mellitus and obesity. Previous autopsy series have reported prevalence of fatty liver disease to be 11%-24%. Recent studies, using imaging and serology, suggest a prevalence of 20%-35%, NASH of 5% and advanced fibrosis of 2%-3%. We examined the preva...
Cartwright, Ashley Snowden, John A Whitehouse, Helen Scott, Stuart Whitby, Liam
Published in
Journal of clinical pathology
Haematological malignancies represent a diverse group of diseases with complex diagnostic requirements. National Institute for Health and Care Excellence (NICE) Haematological Cancer: Improving Outcomes Guidance was published in 2003 and updated in 2016 (NG47), providing recommendations for service delivery including Specialist Integrated Haematolo...
Pozdnyakova, Olga Niculescu, Radu Stefan Kroll, Tracey Golemme, Lisa Raymond, Nolan Briggs, Debra Kim, Annette
Published in
Journal of clinical pathology
Given the time, expense and clinical expertise required for a myelodysplastic syndrome (MDS) diagnosis, there is a clear need for a cost-effective screening laboratory test that can rapidly and accurately distinguish patients with cytopenias related to MDS from other causes. We measured conventional and research use only complete blood cell (CBC) p...
Neyaz, Azfar Rickelt, Steffen Yilmaz, Omer H Parrack, Paige H Lu, Chenyue Yilmaz, Osman Wu, Elizabeth Y Choi, Won-Tak Gala, Manish Ting, David T
...
Published in
Journal of clinical pathology
The lack of accepted scoring criteria has precluded the use of p53 in routine practice. We evaluate the utility of automated quantitative p53 analysis in risk stratifying Barrett's oesophagus (BE) patients using non-dysplastic BE (NDBE) biopsies in a multicentric cohort of BE progressor (P) and non-progressor (NP) patients. NDBE biopsies prior to t...
Finall, Alison Murphy, Kate Frazer, Ricky Dylan
Published in
Journal of clinical pathology
The aim of this quality improvement project was to improve the turnaround time of B-raf proto-oncogene (BRAF) mutation testing in patients with malignant melanoma to support oncologists in making timely treatment decisions. This is a prospective in-house verification of the Idylla BRAF test as compared with DNA panel next-generation sequencing (NGS...
Bhardwaj, Neha Rohilla, Manish Trehan, Amita Bansal, Deepak Kakkar, Nandita Srinivasan, Radhika
Published in
Journal of clinical pathology
Risk stratification as per the International Neuroblastoma Risk Group (INRG) stratification is important for management of neuroblastoma. INRG incorporates various parameters including histological category as per the International Neuroblastoma Pathology Classification (INPC) and MYCN amplification, which were evaluated in fine needle aspiration b...
Steyn, Nicolene
Published in
Journal of clinical pathology
Qin, Jiachun He, Jun Li, Yang Liu, Nansong Tao, Fangchao Zhang, Pengyi Guo, Weilin Qin, Qiongzhen Zhou, Wanjun
Published in
Journal of clinical pathology
Alpha-thalassaemia is one of the most common monogenic disorders worldwide. Due to high guanine-cytosine (GC) content and high mutation diversity in α-globin gene cluster, deletional and non-deletional mutations were usually separately detected with different methods. The aim of this study was to develop a novel one-step method for α-thalassaemia g...
Meyer, Benjamin J Dale, Leigh-Anne Kuo, Selena Z Brandes, Steven B Lagana, Stephen Michael O'Toole, Kathleen M Burt, Joseph E Krishnareddy, Suneeta
Published in
Journal of clinical pathology
Johnson, Lori McCune, Bryan Locke, Darren Hedvat, Cyrus Wojcik, John B Schroyer, Caitlin Yan, Jim Johnson, Krystal Sanders-Cliette, Angela Samala, Sujana
...
Published in
Journal of clinical pathology
A robust immunohistochemistry (IHC) assay was developed to detect lymphocyte-activation gene 3 (LAG-3) expression by immune cells (ICs) in tumour tissues. LAG-3 is an immuno-oncology target with demonstrable clinical benefit, and there is a need for a standardised, well-characterised assay to measure its expression. This study aims to describe LAG-...